Group 1: Clinical Trial Results - Relay Therapeutics' zovegalisib demonstrated a median progression-free survival (PFS) of 11.1 months in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer [1] - Median PFS was 11.2 months in patients with kinase mutations and 11.0 months in patients with non-kinase mutations [1][2] Group 2: Safety Profile - The safety profile of the 400mg BID fed regimen was consistent with previous findings from the 600mg BID fasted dose, reinforcing the drug's potential as a treatment option [2] Group 3: Stock Performance - Relay Therapeutics shares increased by 195.16% over the past 12 months, currently trading 8.6% above its 20-day simple moving average (SMA) and 30.3% above its 100-day SMA [3] - The RSI is at 60.72, indicating neutral territory, while the MACD is at 0.5310, suggesting bullish momentum [3][4] Group 4: Analyst Consensus - The stock carries a Buy Rating with an average price target of $17.20, with recent analyst actions including Guggenheim raising the target to $22.00 and Wells Fargo raising it to $15.00 [5][6] - Benzinga Edge scorecard indicates strong momentum, with a bullish score of 98.01, showing that the stock is outperforming the broader market [5] Group 5: Price Action and Support/Resistance Levels - Relay Therapeutics shares were down 1.45% at $10.21 at the time of publication, with key resistance at $11.50 and key support at $9.00 [6]

Core Insights - The presentation at the 46th Annual TD Cowen Healthcare Conference highlighted Relay Therapeutics' focus on advancing its lead drug candidate, zovegalisib, a PI3K mutant selective molecule, as a key priority for the upcoming year [2]. Company Strategy - Relay Therapeutics has made deliberate choices over the past few years to build a strong foundation, allowing the company to concentrate its resources on zovegalisib [2]. - The company has strategically focused its research organization and staggered the entry of its preclinical programs targeting NRAS and Fabry [3]. - Relay Therapeutics out-licensed its most advanced clinical program, lirafugratinib, to extend its operational runway and focus on its core projects [3]. Industry Context - The discussion included insights into vascular malformations, which is identified as a new and significant area of interest for the company, alongside breast cancer [1].

Company Overview - Relay Therapeutics (RLAY) reported earnings in late February, indicating that spending remains high due to ongoing zovegalisib trials [1] Analyst Background - The analyst has a Master's degree in Cell Biology and extensive experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms, first-in-class therapies, or platform technologies [1] Investment Approach - The investment strategy combines scientific expertise with financial and market analysis to evaluate drug candidates, competitive landscapes, clinical trial designs, and market opportunities [1] - The goal is to provide insights that help investors understand both opportunities and risks in the biotech sector, which can yield significant returns but requires careful scrutiny [1]

Summary of Relay Therapeutics FY Conference Call Company Overview - **Company**: Relay Therapeutics (NasdaqGM: RLAY) - **Key Speakers**: Sanjiv Patel (President and CEO), Peter Rahmer (Chief Corporate Development Officer), Don Bergstrom (President of R&D) Core Industry Focus - **Primary Areas of Focus**: - Vascular malformations - Breast cancer - **Key Product**: Zovegalisib, a PI3K mutant selective molecule Key Points and Arguments Financial and Strategic Positioning - Relay Therapeutics has made deliberate choices to focus capital on advancing zovegalisib, extending cash runway into 2029 [2][3] - The company outlicensed its most advanced clinical program, lirafugratinib, to concentrate on three large clinical areas: - 2nd line hormone receptor-positive, HER2-negative breast cancer - 1st line metastatic hormone receptor HER2-negative breast cancer - PI3K driven vascular anomalies [2][3] Clinical Data and Upcoming Disclosures - Upcoming data disclosures include: - 2nd-line metastatic breast cancer data at ESMO TAT in Paris [3] - Data from 57 patients on a 400 mg BID fed dose, expected to show consistency with previous data [4] - Vascular anomalies data from 20 patients at the 12-week efficacy endpoint [5][6] Vascular Malformations Insights - Vascular malformations are driven by PI3K mutations, with previous proof of concept from non-selective PI3K inhibitors [9] - The company aims to show meaningful differentiation in response rates for zovegalisib compared to existing treatments [9][10] - There are approximately 170,000 PIK3CA-driven vascular anomaly patients in the U.S., with about 100,000 in the three subtypes of interest [15][16] - The company estimates that 25,000 of these patients would seek chronic systemic therapy [17] Trial Design and Regulatory Considerations - The ReInspire trial is designed to evaluate zovegalisib across three different dose levels, with a focus on safety and tolerability [20][21] - The primary endpoint for potential accelerated approval is the objective response rate (ORR), with a target of a 20% reduction in lesion volume [25] - The company aims to exceed the response rates of existing treatments, which range from 11% to 27% [25] Safety and Tolerability - Safety and tolerability are critical, as the treatment will be chronic, starting in childhood [26][28] - The company is focused on achieving a favorable risk-benefit profile to support long-term treatment decisions [26][28] Competitive Landscape - Zovegalisib is positioned against other treatments like alpelisib and sirolimus, with a focus on differentiating its patient population and treatment approach [30][32] - The company believes that the patient populations for zovegalisib and competing treatments will not significantly overlap [30][32] Breast Cancer Developments - The company is also advancing its breast cancer programs, with plans to share data on combination therapies and trial designs [41][50] - The focus is on ensuring tolerability in long-term treatment regimens, particularly in combination with CDK4/6 inhibitors [43][55] Additional Important Insights - The company is actively enrolling patients globally in its trials and is optimistic about the progress made so far [50] - There is ongoing interest in exploring combinations with SIRD agents in the future [61] This summary encapsulates the key points discussed during the Relay Therapeutics FY Conference Call, highlighting the company's strategic focus, clinical developments, and competitive positioning in the biotech industry.

Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on precision medicines for oncology and genetic diseases, utilizing advanced computational modeling and partnerships to develop small-molecule therapies targeting key disease pathways [5] - The company has a market capitalization of $1.9 billion and reported a revenue of $8.36 million for the trailing twelve months (TTM), with a net income loss of $297.59 million [4] Recent Developments - On February 17, 2026, Casdin Capital disclosed an increase in its holding of Relay Therapeutics by 1,662,193 shares, raising its total to 13,003,574 shares, with an estimated transaction value of $11.86 million [2][6] - The quarter-end value of Casdin's position in Relay increased by $50.81 million, reflecting both additional purchases and stock price movements [2] Financial Position - Relay Therapeutics ended 2025 with approximately $555 million in cash, cash equivalents, and investments, which is expected to fund operations into 2029 [10] - The company reported a full-year net loss of $276.5 million, with elevated research spending [10] Stock Performance - As of the last reported price, Relay shares were valued at $10.95, representing a 235% increase over the past year, significantly outperforming the S&P 500's approximately 15% gain during the same period [6] Pipeline and Future Prospects - Relay is advancing several lead candidates, including RLY-4008, RLY-2608, and RLY-1971, and is focused on small molecule therapeutics for targeted oncology and genetic diseases [7] - The company anticipates multiple data disclosures in 2026, including Phase 1 data related to PIK3CA-driven vascular anomalies and updates on breast cancer triplet strategies involving its lead asset, zovegalisib, which is currently in a Phase 3 trial for HR positive, HER2 negative metastatic breast cancer [9]

Core Insights - Relay Therapeutics is entering a pivotal period in 2026 with multiple clinical milestones for its lead program, zovegalisib, which has received Breakthrough Therapy designation from the FDA [2] Financial Performance - As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling approximately $554.5 million, a decrease from $781.3 million at the end of 2024 [6][21] - Revenue for Q4 2025 was $7.0 million, compared to $0 for Q4 2024, and total revenue for the full year 2025 was $15.4 million, up from $10.0 million in 2024 [7] - Research and development expenses for Q4 2025 were $55.4 million, down from $68.1 million in Q4 2024, while full-year R&D expenses decreased to $261.4 million from $319.1 million [8] - General and administrative expenses for Q4 2025 were $12.2 million, down from $16.9 million in Q4 2024, and full-year G&A expenses decreased to $56.7 million from $76.6 million [9] - The net loss for Q4 2025 was $54.9 million, or $0.32 per share, compared to a net loss of $76.0 million, or $0.45 per share, in Q4 2024 [10] Clinical Development - Initial Phase 1 data for zovegalisib in PIK3CA-driven vascular anomalies is expected in the first half of 2026, with a pediatric cohort recently opened ahead of schedule [5] - The company plans to present Phase 1/2 breast cancer data at the ESMO TAT Congress on March 16, 2026, focusing on patients with HR+/HER2- metastatic breast cancer [5] - The Phase 3 ReDiscover-2 trial of zovegalisib in advanced breast cancer continues, with data from the Phase 1/2 trial showing a median progression-free survival of 10.3 months and an objective response rate of 39% among patients with measurable disease [5][13] Product Overview - Zovegalisib is a novel PI3Kα inhibitor designed to selectively target mutant forms of the enzyme, addressing significant patient populations with HR+/HER2- breast cancer and vascular anomalies driven by PI3Kα mutations [11][15] - The drug has the potential to serve approximately 140,000 patients with HR+/HER2- breast cancer and 170,000 patients with vascular anomalies in the U.S. annually [11]

Company Overview - Relay Therapeutics is a clinical-stage, small molecule precision medicine company focused on developing therapies for cancer and genetic diseases [2] - The company's lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer [2] - Relay's pipeline includes programs targeting NRAS-driven solid tumors and Fabry disease, in addition to zovegalisib's investigation in PI3Kα-driven vascular anomalies [2] Upcoming Events - Management will participate in two fireside chats in March 2026, which will be webcast live and accessible through the company's website [1] - The TD Cowen 46th Annual Health Care Conference is scheduled for March 2, 2026, at 3:10 p.m. ET [3] - The Barclays 28th Annual Global Healthcare Conference will take place on March 11, 2026, at 10:30 a.m. ET [3]

Core Insights - Relay Therapeutics is a clinical-stage company focused on developing small molecule precision medicine for cancer and genetic diseases [2] - The company will report its fourth quarter and full year 2025 financial results on February 26, 2026 [1] Company Overview - Relay Therapeutics utilizes its Dynamo® platform, which combines advanced computational and experimental methods to target previously difficult-to-drug proteins [2] - The lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in Phase 3 trials for HR+/HER2- metastatic breast cancer [2] - Zovegalisib is also being studied for PI3Kα-driven vascular anomalies and the company has additional programs targeting NRAS-driven solid tumors and Fabry disease [2]

Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on precision small molecule therapies using computational modeling and structure-based drug design to address unmet needs in oncology and genetic diseases [1] - The company has a pipeline of innovative candidates and strategic collaborations with industry leaders, positioning it to advance next-generation targeted therapies [1] Business Model - Relay Therapeutics operates a clinical-stage biotechnology business model, generating revenue primarily through collaboration and license agreements with partners such as Genentech and D.E. Shaw Research, with future revenue expected from product commercialization [2] Insider Transactions - Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 21,581 shares for approximately $166,700 on January 27 and 28, 2026, as disclosed in the SEC Form 4 filing [5] - This transaction represented 4.89% of Bergstrom's direct ownership, significantly higher than the recent median percentage of holdings disposed per open-market sale [4] - The sale was primarily to cover income tax withholding obligations after the vesting of restricted stock units (RSUs), indicating that it was not a discretionary sale [6] Stock Performance - Relay Therapeutics' stock has increased nearly 70% since January 28, 2025, and received a Breakthrough Therapy designation from the FDA for zovegalisib in advanced breast cancer treatment, leading to a 6% stock price increase to $8.65 [6] - The company has received positive attention from Wall Street, with upgrades from Wells Fargo and Oppenheimer, and an analyst consensus rating of moderate buy with an average price target of $16.57 [6] Investment Considerations - Despite the positive developments, Relay Therapeutics was not included in a recent list of the top 10 stocks recommended by the Motley Fool Stock Advisor, which could indicate a cautious approach for potential investors [7]

Core Insights - Relay Therapeutics, Inc. is a clinical-stage company focused on developing small molecule precision medicine therapies for cancer and genetic diseases [3] Group 1: Company Overview - Relay Therapeutics is developing potentially life-changing therapies for patients with cancer and genetic diseases [3] - The company's lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor in clinical development, currently in a Phase 3 trial for HR+/HER2- metastatic breast cancer [3] - Relay's pipeline includes programs targeting NRAS-driven solid tumors and Fabry disease, in addition to zovegalisib's investigation in PI3Kα-driven vascular anomalies [3] Group 2: Upcoming Events - Management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026, at 10:30 a.m. ET [1] - The fireside chat will be webcast live and accessible through Relay Therapeutics' website, with an archived replay available for 30 days post-event [2]